Teva Pharmaceutical (TEVA) Tops Q1 EPS by 2c

Teva Pharmaceutical (NYSE: TEVA) reported Q1 EPS of $1.22, $0.02 better than the analyst estimate of $1.20. Revenue for the quarter came in at $5 billion versus the consensus estimate of $5.11 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c